Funded Biotechnology Startups
The 29 most recent funding rounds in this segment span September through late November 2025, drawing capital across the US, China, and a wide spread of Eur…
The 29 most recent funding rounds in this segment span September through late November 2025, drawing capital across the US, China, and a wide spread of European and Asian markets. Series A is the dominant stage—nine of the 29 rounds—anchored by two unusually large closes: Adcytherix in Marseille raised $122M and Ollin Biosciences in Austin raised $100M. At the lower end of the spectrum, Chirality Biosciences (Farmingdale) closed a $3M Seed and AltrixBio (Cambridge) raised $5M at Series A.
US-headquartered companies account for 11 of the 29 entries, with California cities—La Jolla, San Francisco, Foster City, and San Diego—contributing five alone. China follows with nine companies, three of them in Hangzhou: Healsun Biopharm, Kind Pharmaceutical, and Vybio. European activity includes 4TEEN4 Pharmaceuticals ($36M Series C, Hennigsdorf), two Marseille-based Series A raises (Adcytherix and Tafalgie Therapeutics), and early-stage companies in Spain, Portugal, and the Netherlands.
Most recent rounds
29 shownRelated listings
Frequently asked
What are the largest disclosed funding rounds in this cohort?
The five largest disclosed amounts are Adcytherix ($122M Series A, Marseille), Ollin Biosciences ($100M Series A, Austin), AusperBio ($63M Series B, Foster City), Kind Pharmaceutical ($56M Series C, Hangzhou), and OncoC4 ($50M Series B, Rockville). Notably, the two largest rounds—both over $100M—are Series A raises, not later-stage rounds.
Which geographies are most active for biotech and pharma fundraising in this dataset?
The US leads with 11 companies across Cambridge, La Jolla, San Francisco, Foster City, San Diego, Scottsdale, Rockville, Farmingdale, and Austin. China follows with nine companies, concentrated in Hangzhou (Healsun Biopharm, Kind Pharmaceutical, Vybio) and Shanghai (Brise Pharma, Changsen Pharmaceutical). France, Germany, South Korea, Japan, Spain, Portugal, and the Netherlands each contribute one or two entries.
What funding stage is most common among recently funded biotech and pharma companies?
Series A accounts for nine of the 29 rounds, making it the most frequent stage. Series B follows with seven rounds, Seed with five, Series C with four, and three rounds are classified as Venture - Series Unknown.
How significant is European biotech fundraising in this cohort?
European companies account for six of the 29 rounds. The largest is Adcytherix in Marseille at $122M Series A, followed by 4TEEN4 Pharmaceuticals (Hennigsdorf, Germany) at $36M Series C and Tafalgie Therapeutics (also Marseille) at $14M Series A. Spain, Portugal, and the Netherlands each have one early-stage company with undisclosed amounts.
What share of rounds have undisclosed amounts?
Ten of the 29 rounds list undisclosed amounts—roughly one in three. These span all stages, from Seed (Miramoon Pharma, Appfinder Therapeutics, Cantoni Therapeutics) to Series B (Changsen Pharmaceutical, VS PharmTech, Affinity) and Series A (Norn Gene, Mondego Bio, RabPharma), with Healsun Biopharm's Series C also undisclosed.
How do Series C rounds in this cohort compare in size?
Four Series C rounds appear in the data: Kind Pharmaceutical ($56M, Hangzhou), 4TEEN4 Pharmaceuticals ($36M, Hennigsdorf), and SelectION ($5M, San Diego), with Healsun Biopharm (Hangzhou) undisclosed. The gap between $5M and $56M at the same stage reflects the wide variance in capital requirements across therapeutic focus areas and geographies.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.